| Yesterday |
| 12:52 AM |
|
8 HealthCare Stocks With 3%+ Dividends
Hao Jin submits: In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single-digit pace in the second year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs, which pay virtually no interest at all, and long-term bonds, which pay a little bit more but leave you at the mercy of inflation.
Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer ( PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Pfizer plus Automated Data Processing ( ADP), Johnson & Johnson ( JNJ), ExxonMobil ( XOM) and Microsoft ( MSFT). In other words, 2 out of 5 were healthcare companies. Major HealthCare Companies I covered healthcare plans stocks such as UnitedHealth Group ( UNH) in my Oct 25 article. Following are major healthcare companies in other subsectors inside the health care sector, sorted by yield: Name (Symbol) | Industry | P/E | Forward P/E | Yield | | Drug Manu. | N/A | 8 | 5.2% | | Drug Manu. | 13 | 12 | 4.8% | | Drug Manu. | 13 | 12 | 4.6% | | Drug Manu. | 10 | 10 | 4.2% | | Drug Manu. | N/A | 8 | 3.6% | | Drug Manu. | 15 | 8 | 3.4% | | Drug Manu. | 14 | 13 | 3.1% | | Drug Manu. | 17 | 13 | 3.1% | | Drug Manu. | 15 | 13 | 2.9% | | Medical Instru | 23 | 20 | 2.6% | | Drug Manu. | 9 | 8 | 2.5% | | Medical Instru | 15 | 13 | 1.9% | | Medical Appli | 25 | 12 | 1.9% | | Drug Manu. | 18 | 16 | 1.1% | Teva Pharmaceutical (TEVA) | Drug Manu. | 48 | 12 | 0.9% | | Biotechnology | 12 | 11 | 0.0% | | Biotechnology | 18 | 15 | 0.0% | Average | n/a | 18 | 12 |
The top 8 companies in the above list yielding more than 3% are all major drug manufacturers. Some of them have single digit forward P/E. H1N1 could benefit vaccine-makers including Novartis ( NVS), Sanofi-Aventis ( SNY), and AstraZeneca ( AZN). On November 25, U.S. health officials said that they are seeing a worrying pattern of serious bacterial infections in swine flu patients, mostly among younger adults not normally vulnerable to them. In addition to pending health care reform, a common problem faces big pharma is that there are patents which will expire between 2010 and 2012. However, this industry has been looking to fuel growth via acquisitions, including blockbuster deals. Pharmaceutical giants are also looking to pick up some biotech companies to boost their pipelines. Biotech Biotechnology probably offers the best level of innovation of any of the healthcare industries. Its P/E is low too. For example, Amgen (AMGN)’s P/E is only 12. Although my core holdings are boring blue chip dividend stocks, I also allocated a very small portion of my portfolio in promising small caps. China Biologic Products ( CBPO.OB) is one of leading plasma-based biopharmaceutical company in China. For the first nine months of 2009, its total revenue was $81 million, up 142% from 2008. It has $50 million in cash and low debt. However, traded in OTC bulletin board, the stock price was extreme volatile. It also has derivative liabilities which might potentially affect its future income. Top 10 HealthCare ETFs ( by Net Assets) Fund Name (Ticker) | Net Assets | Earnings Growth Rate (ttm) | Health Care Select Sector SPDR (XLV) | 1.93B | 8% | Pharmaceutical HOLDRs (PPH) | 1.52B | 6% | iShares Nasdaq Biotechnology (IBB) | 1.35B | 16% | | 728M | 13% | iShares Dow Jones US Healthcare (IYH) | 582M | 9% | Vanguard Health Care ETF (VHT) | 538M | 10% | iShares S&P Global Healthcare (IXJ) | 439M | 9% | | 371M | 21% | iShares Dow Jones US Medical Devices (IHI) | 269M | 13% | PowerShares Dynamic Biotech & Gen (PBE) | 183M | 17% |
Conclusion During the relatively benign 20-year period prior to 2008, most portfolios accumulated considerable short volatility biases, which looked very attractive to investors as a result of recent positive performance. It was this growing short volatility bias that created so much pain in the current downturn, according to CFA Digest November 2009 issue. Buying after a 40% decline is not a safe bet for investor. Markets may continue to fall and often have no trouble reaching a bottom of 75% below peak. Recent examples include 1989’s Japan Nikkei index, 2000’s NASDAQ, 2007’s China market and 2008’s oil/natural gas prices. So if investors think the environment will remain volatile, they should look for stocks with a lower sensitivity to volatility. Even if they make fewer profits for you on the way up, they lose a lot less on the way back down. With its forward average P/E of 12 and beta of 0.69, healthcare might be a great defensive sector. For those who need stable income, big pharmaceutical companies may be a good choice. Disclosure: I have long positions on PPH and CBPO.OB. Complete Story »
|
Seeking Alpha
|
| Saturday, November 28, 2009 |
| 07:50 PM |
|
Taking A Look At Two Pharma ETFs (IHE, PPH)
When it comes to ETF plays on the domestic pharma sector, investors have two options when it comes to playing the blue chip names in the space. The Pharmaceutical HOLDRs (AMEX: PPH) and the iShares Dow Jones US Pharmaceuticals ETF (NYSE: IHE) are the ETFs to consider.
On the surface, IHE and PPH look similar as both ETFs count many of the same names among their top holdings. Abbott Labs (NYSE: ABT), Merck (NYSE: MRK) and Pfizer (NYSE: PFE) are all among the top-10 holdings in both ETFs.
Yet over the last three months, IHE has outperformed PPH by about 10% even though PPH has a much higher average daily volume.
IHE is more diversified. It's biggest holding, Johnson & Johnson (NYSE: JNJ) accounts for about 8% of assets, where as the top four holdings in PPH, Abbott, JNJ, Merck and Pfizer account for 55% of that ETF's assets.
So the bottom line is, the ETF Profesor says lean toward IHE if you're considering purchasing a pharma ETF.
|
Benzinga
|
| Friday, November 27, 2009 |
| 08:30 AM |
|
Abbott Laboratories (ABT) 11/27/09 PriceWatch Alert Support Down To $53.89
Abbott Laboratories (NYSE: ABT) closed yesterday at $54.41. So far the stock has hit a 52-week low of $41.27 and 52-week high of $57.39. Abbott Laboratories stock has been showing support around 53.89 and resistance in the 54.85 range. Technical indicators for the stock are Bullish and S&P gives ABT a positive 4 ...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)
|
MarketIntelligenceCe...
|
| 06:18 AM |
|
A Mostly Meaningless FDA Approval
After an accelerated approval, the positive effects of a full approval are minimal.
|
Fool.com Headlines
|
| Thursday, November 26, 2009 |
| 08:28 AM |
|
Abbott Laboratories (ABT) 11/27/09 PriceWatch Alert Support Down To $53.89
Abbott Laboratories (NYSE: ABT) closed yesterday at $54.41. So far the stock has hit a 52-week low of $41.27 and 52-week high of $57.39. Abbott Laboratories stock has been showing support around 53.89 and resistance in the 54.85 range. Technical indicators for the stock are Bullish and S&P gives ABT a positive 4 ...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)
|
MarketIntelligenceCe...
|
| 12:46 AM |
|
(BSX) Boston Scientific Earns FDA Clearance
Boston Scientific Corp. (BSX) recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent in the U.S. and Europe. The new product is used for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable [...]
(BSX) Boston Scientific Earns FDA Clearance
|
Stock Blog Hub
|
| 12:01 AM |
|
An extra Thanksgiving for Linde Equity Report
Editor Teal Linde won’t be celebrating Thanksgiving today. But maybe he should -- his Linde Equity Report is having a thanks-worthy year, writes Peter Brimelow.
|
MarketWatch
|
| Wednesday, November 25, 2009 |
| 02:31 PM |
|
Boston Scientific’s New Product – Analyst Blog
Boston Scientific Corp. ( BSX) recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent in the U.S. and Europe. The new product is used for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.
With the new approval, Boston’s complete portfolio of WallFlex Stent family of self-expanding metal stents is now available in the U.S. , Europe and other international markets. The company had earlier received approval for marketing the WallFlex Partially Covered Esophageal Stent in U.S. and Europe in 2008.
The WallFlex Fully and Partially Covered Stents prevent tumor ingrowth by using a proprietary Permalume silicone covering. This also reduces the impaction of food. It is seen that patients suffering from esophageal cancer may have difficulties in swallowing, even while consuming liquids. The WallFlex Esophageal Stent prevents this by re-establishing patency (openness) of the esophagus. This in turn makes life easier for patients.
We think that the unique features of the WallFlex Fully Covered Stents are likely to make them widely acceptable amongst surgeons. This will boost demand for these stents which will increase the company’s top-line.
Boston Scientific is a manufacturer of medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. The primary competitors include Johnson & Johnson ( JNJ), Medtronic Inc. ( MDT), Abbott Laboratories ( ABT) and St. Jude Medical Inc. ( STJ). Read the full analyst report on "BSX"Read the full analyst report on "JNJ"Read the full analyst report on "MDT"Read the full analyst report on "ABT"Read the full analyst report on "STJ"Zacks Investment Research
|
Stock Market News & ...
|
| 01:14 PM |
|
(GPRO) Gen-Probe Earns U.S. Food and Drug Administration Approval
Recently, Gen-Probe Inc. (GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2, and 3 viruses that cause lower respiratory tract infections.
The [...]
(GPRO) Gen-Probe Earns U.S. Food and Drug Administration Approval
|
Stock Blog Hub
|
| 01:05 PM |
|
Abbott Lab management to meet with RBC Capital
See the rest of the story here.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
|
theflyonthewall.com
|
| 12:57 PM |
|
FDA Nod for Gen-Probe Assay – Analyst Blog
Recently, Gen-Probe Inc. ( GPRO) announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2, and 3 viruses that cause lower respiratory tract infections.
The assay makes use of real-time polymerase chain reaction to identify parainfluenza 1, 2, and 3 viruses from nasal swabs. Since it utilizes the same internal control as Prodesse's other tests for respiratory infectious diseases, a single nucleic acid extract can be tested with any combination of its other products which have received FDA clearance - ProFlu Plus, Pro hMPV Plus and ProFlu-ST.
As a reminder, ProFlu Plus received FDA approval in 2008 for detecting and differentiating influenza A and B viruses and respiratory syncytial virus (RSV). Pro hMPV Plus got FDA clearance in the same year to detect human metapneumovirus. ProFlu-ST is available for use under an FDA emergency use authorization in CLIA (Clinical Laboratory Interstate Act) high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus.
We believe that the addition of ProFlu Plus to Gen-Probe’s already established product portfolio of molecular tests for respiratory infectious diseases further enhances its reputation in the field of molecular diagnostics. It will aid doctors in the accurate identification of parainfluenza virus infections, particularly when the prevalence of other viruses is on the higher side. Management further stated that results from tests using the company’s assays can be obtained within three hours as against a week taken by culture-based methods to come out with a result.
Gen-Probe Inc., a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing (NAT) products that are used for the diagnosis of human diseases and for screening donated human blood. The utilization of the NAT technology has enabled the company to obtain FDA approvals for more than 40 products that detect a wide variety of infectious microorganisms such as strep throat, pneumonia and fungal infections. The company competes with players like Abbott Laboratories ( ABT) and Roche ( RHHBY). Read the full analyst report on "GPRO"Read the full analyst report on "ABT"Read the full analyst report on "RHHBY"Zacks Investment Research
|
Stock Market News & ...
|
| 10:20 AM |
|
A Big Upgrade for Amylin Pharmaceuticals
This bullish call comes from more than just one analyst.
|
Fool.com Headlines
|
| 09:51 AM |
|
Merck cholesterol scrips drop as Niaspan rises
Last week, all eyes were on Merck's cholesterol drugs. How did Zetia do in that much-anticipated study pitting it against Abbott Laboratories' Niaspan treatment? Well, the American Heart Association meeting has come and gone, and while the study favored Niaspan, the even-handed media coverage pointed out the trial's shortcomings as well...
|
News items | BNET
|
| 09:41 AM |
|
Novartis Didn't Know JAK, Until Now
A drug deal Jellyvision could be proud of.
|
Fool.com Headlines
|
| 08:26 AM |
|
Abbott Laboratories (ABT) PriceWatch Alert for November 25, 2009
Abbott Laboratories (NYSE: ABT) closed yesterday at $54.24. So far the stock has hit a 52-week low of $41.27 and 52-week high of $57.39. Abbott Laboratories stock has been showing support around 51.75 and resistance in the 55.73 range. Technical indicators for the stock are Bullish and S&P gives ABT a positive 4 ...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)
|
MarketIntelligenceCe...
|
| 06:38 AM |
|
7 All-Star Stocks to Make Your Portfolio Shine
Some solid businesses for your watch list.
|
Fool.com Headlines
|
| Tuesday, November 24, 2009 |
| 06:47 PM |
|
Fast Money Picks For November 25th (F, ABT, BSX, BRCD)
CNBC's Fast Money Tim Seymour thinks that investors should take profits in Ford (NYSE: F) because it typically fails at $9. Ford (F) gained 0.92% today and closed at $8.81.
Guy Adami recommends buying Abbott Laboratories (NYSE: ABT), and Karen Finerman suggests buying Boston Scientific (NYSE: BSX) on the heels of good Medtronic (NYSE: MED) earnings. Abbott Laboratories gained 2.09% today, while Boston Scientific (BSX) added 4.90%.
Pete Najarian wants to buy Brocade Communications Systems (NASDAQ: BRCD) after a big pullback today. Brocade (BRCD) dropped 8.95% today and closed at $7.10.
|
Benzinga
|
| 10:57 AM |
|
52-Week Highs! What's Going On?
Even with its recent leap, this stock may belong in your portfolio.
|
Fool.com Headlines
|
| 02:56 AM |
|
Upside Should Continue to Be Driven by 'Game Theory'
|
Seeking Alpha
|
| 01:04 AM |
|
(ABT) Abbott Labs Deals for Drug Candidate
Abbott Labs (ABT) recently signed a definitive agreement with PanGenetics BV for a pain candidate, PG110. Under the terms of the agreement, Abbott will acquire global rights to PG110 which is a novel biologic that targets Nerve Growth Factor (NGF) for the treatment of chronic pain.
PanGenetics will receive an upfront payment of $170 million and [...]
(ABT) Abbott Labs Deals for Drug Candidate
|
Stock Blog Hub
|
| |
More All For ABT
|
|